ROCKET PHARMACEUTICALS, INC. 8-K

What Happened
Rocket Pharmaceuticals, Inc. announced that on June 10, 2026 it completed the previously disclosed sale of its Rare Pediatric Disease Priority Review Voucher (PRV) to a large pharmaceutical company, receiving gross cash proceeds of $180.0 million. The PRV had been issued in connection with the FDA approval of KRESLADI™ (marnetegragene autotemcel) for treating pediatric patients with severe leukocyte adhesion deficiency‑I (LAD‑I). The sale was completed under an asset purchase agreement dated April 26, 2026; a copy of the PRV APA will be filed with Rocket’s Form 10‑Q for the quarter ended June 30, 2026. The company also furnished a press release dated June 12, 2026 announcing the closing.

Key Details

• Closing date: June 10, 2026.
• Buyer: described as a “large pharmaceutical company” (unnamed in the 8‑K).
• Consideration: gross proceeds of $180.0 million paid at closing.
• Origin of PRV: issued upon FDA approval of KRESLADI™ (marnetegragene autotemcel) for severe LAD‑I.

Why It Matters
This is a material, one‑time cash inflow from the sale of a regulatory asset (the PRV), which increases Rocket’s liquidity and may affect near‑term cash runway and financing needs. The proceeds are reported as gross; investors should look to upcoming filings (the June 30, 2026 Form 10‑Q) for how the company records the transaction, any related expenses or taxes, and full agreement terms. The 8‑K also notes that contractual representations and warranties in the PRV APA are limited to the parties and should not be taken as independent factual statements.